Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Latest updates on liso-cel for R/R CLL/SLL

David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the latest research investigating lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), including updates from the ongoing Phase I TRANSCEND-CLL-004 study (NCT03331198). This study has found that liso-cel monotherapy achieves a high rate of undetectable measurable residual disease (uMRD), with 75% of patients having uMRD in the blood. Liso-cel has also demonstrated a manageable safety profile and promising efficacy in combination with ibrutinib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.